A Phase 4 interventional study of pregabalin and celecoxib and Placebo and celecoxib in Chronic Low Back Pain With a Neuropathic Component, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 30 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Low Back Pain with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Low Back Pain · Mexico.
Among the 11 studies in Low Back Pain with a site in Mexico, this one is the only one that started in 2013, is one of 2 in phase 4, and was the 4th registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →2 of the 11 studies in Low Back Pain with a site in Mexico are open now. Recruiting first, the newest first:
ISSSTE Hospital Regional "Gral. Ignacio Zaragoza" · Sites in Mexico
Ages 18–75
Armando Tonatiuh Avila Garcia · Sites in Mexico
Ages 18–80
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 60 across 2,364 interventional studies indexed under Low Back Pain.
Median enrollment 177 across the 8 interventional studies, 50 across the 3 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 8 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Low Back Pain with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07929623ISSSTE Hospital Regional "Gral. Ignacio Zaragoza"Fluoroscopy-Guided Lumbar Facet Block for Chronic Low Back Pain | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Low Back Pain with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if treatment with celecoxib and pregabalin together would prove to be more effective in relief of pain than treatment with celecoxib alone in people who have chronic low back pain with a probable neuropathic component.
The primary objective is to evaluate the efficacy of the concomitant use of pregabalin and celecoxib compared with celecoxib monotherapy for the symptomatic relief of pain in patients with chronic low back pain with a probable neuropathic component.
The secondary objectives are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
Drug: pregabalin and celecoxib
The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
Drug: Placebo and celecoxib
Drug pages: Pregabalin · Celecoxib
During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily. All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily. All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
Change From Baseline in the Weekly Mean Pain Numeric Rating Scale (NRS) Score at Week 5 (ie, Visit 4) Compared Between the Two Study Arms
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
Time frame: Baseline and Week 5
Change in the Weekly Mean Pain NRS Score in Arm B, Compared Between Week 5 (Visit 4) and Week 10 (Visit 6).
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
Time frame: Week 5 and Week 10
Change From Baseline in the Weekly Mean Pain NRS Score at Week 10 (Visit 6) Compared Between the Two Study Arms
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
Time frame: Baseline and Week 10
Change From Baseline in Benefit, Satisfaction, and Willingness to Continue Measure Scores Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)
The BSW consists of 3, single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was administered by the investigator or designated site personnel in the local language as a standardized interview during the follow-up visits. The BSW can potentially be self-administered; however, this method of administration has not been tested. Participants completed this questionnaire at Visit 4 and Visit 6.
Time frame: Week 5 and Week 10
Patient Global Impression of Change (PGIC) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)
The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.
Time frame: Week 5 and Week 10
Percentage of Participants With PGIC for Each Arm Compared at Week 5 (Visit 4) and at Week 10 (Visit 6)
The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.
Time frame: Week 5 and Week 10
Change From Baseline in Weekly Mean of Daily Sleep Interference Rating Scale (SIRS) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)
The Daily Sleep Interference Rating Scale (SIRS) consists of an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants described how pain had interfered with their sleep during the past 24 hours: Select the number that best describes how your pain has interfered with your sleep during the past 24 hours on a scale from 0 to 10 where 0 represents 'does not interfere with sleep' and 10 represents 'completely interferes' which means you are unable to sleep due to pain.
Time frame: Week 5 and Week 10
Change From Baseline in Hospital Anxiety and Depression Scale (HADS-A) Anxiety Scores at Week 5 (Visit 4) and Week 10 (Visit 6)
The HADS is a self-administered questionnaire measuring anxiety. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No anxiety, to 3 = Severe feelings of anxiety). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the anxiety.
Time frame: Week 5 and Week 10
Change From Baseline in Hospital Anxiety and Depression Scale (HADS-D) Depression Scores at Week 5 (Visit 4) and Week 10 (Visit 6)
The HADS is a self-administered questionnaire measuring depression. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No depression, to 3 = Severe feelings of depression). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the depression.
Time frame: Week 5 and Week 10
Percentage of Days in Mild, Moderate and Severe Pain at Period 1 and Period 2
Period 1 indicates from Visit 2 (baseline) to Visit 4 (Week 5). Period 2 indicates from Visit 4 (Week 5) to Visit 6 (Week 10). A rating of 0 is considered no pain; 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.
Time frame: Period 1 and Period 2
Change From Baseline in Brief Pain Inventory Short Form (BPI sf) - Pain Severity Index Score at Week 5 and Week 10
BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the past 24 hours. The Pain severity domain: The BPI severity domain includes pain at its 'worst,' 'least,' 'average,' and 'now' (current pain) on 0-10 NRS scales and takes the mean of these 4 items. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine), therefore higher scores indicate greater pain severity.
Time frame: Week 5 and Week 10
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance Subscale at Week 5 and Week 10
The MOS-Sleep Scale is a self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. With the exception of sleep adequacy, optimal sleep, and quantity, higher scores reflect greater impairment in the MOS-Sleep subscales. Sleep Disturbance: Range=0 to 100; higher scores indicate greater sleep disturbance. Negative changes indicate improvement.
Time frame: Week 5 and Week 10
Percentage of Participants With >= 30% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
Time frame: Week 5 and Week 10
Percentage of Participants With >= 50% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
Time frame: Week 5 and Week 10
This study was conducted at 28 sites across 7 countries. From a total of 232 participants screened, 180 were randomized into Period 1 and 166 entered into Period 2.
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 89 | 91 |
| Completed | 81 | 75 |
| Not completed | 8 | 16 |
| Withdrew: Adverse event | 4 | 6 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Insufficient clinical response | 1 | 2 |
| Withdrew: Medication error without associated ae | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Change From Baseline in the Weekly Mean Pain Numeric Rating Scale (NRS) Score at Week 5 (ie, Visit 4) Compared Between the Two Study Arms | -2.18 ± 0.212 | -2.03 ± 0.212 |
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
| Units on a scale | Arm B |
|---|---|
| Change in the Weekly Mean Pain NRS Score in Arm B, Compared Between Week 5 (Visit 4) and Week 10 (Visit 6). | 1.42 ± 0.204 |
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Change From Baseline in the Weekly Mean Pain NRS Score at Week 10 (Visit 6) Compared Between the Two Study Arms | -3.21 ± 0.262 | -3.45 ± 0.265 |
The BSW consists of 3, single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was administered by the investigator or designated site personnel in the local language as a standardized interview during the follow-up visits. The BSW can potentially be self-administered; however, this method of administration has not been tested. Participants completed this questionnaire at Visit 4 and Visit 6.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| Benefit from Treatment - No benefit (Week 5) | 10.1 | 6.6 |
| Benefit from Treatment - Little benefit (Week 5) | 22.5 | 29.7 |
| Benefit from Treatment - Much benefit (Week 5) | 61.8 | 53.8 |
| Satisfaction from Treatment - DVN (Week 5) - Yes | 78.7 | 84.6 |
| Satisfaction from Treatment - DVN (Week 5) - No | 15.7 | 5.5 |
| A Little Satisfied (Week 5) | 20.2 | 26.4 |
| Very Satisfied (Week 5) | 58.4 | 58.2 |
| A Little Dissatisfied (Week 5) | 12.4 | 4.4 |
| Very Dissatisfied (Week 5) | 3.4 | 1.1 |
| Willingness to Continue - DVN (Week 5) - Yes | 94.4 | 89.0 |
| Willingness to Continue - DVN (Week 5) - No | 0 | 1.1 |
| A Little Bit Willing (Week 5) | 5.6 | 4.4 |
| Very Willing (Week 5) | 88.8 | 84.6 |
| A Little Unwilling (Week 5) | 0 | 0 |
| Very Unwilling (Week 5) | 0 | 1.1 |
| Benefit from Treatment - No benefit (Week 10) | 4.5 | 3.3 |
| Benefit from Treatment - Little benefit (Week 10) | 14.6 | 9.9 |
| Benefit from Treatment - Much benefit (Week 10) | 71.9 | 70.3 |
| Satisfaction from Treatment - DVN (Week 10) - Yes | 83.1 | 80.2 |
| Satisfaction from Treatment - DVN (Week 10) - No | 7.9 | 3.3 |
| A Little Satisfied (Week 10) | 9.0 | 11.0 |
| Very Satisfied (Week 10) | 74.2 | 69.2 |
| A Little Dissatisfied (Week 10) | 5.6 | 2.2 |
| Very Dissatisfied (Week 10) | 2.2 | 1.1 |
| Willingness to Continue - DVN (Week 10) - Yes | 88.8 | 81.3 |
| Willingness to Continue - DVN (Week 10) - No | 2.2 | 2.2 |
| A Little Bit Willing (Week 10) | 4.5 | 4.4 |
| Very Willing (Week 10) | 84.3 | 76.9 |
| A Little Unwilling (Week 10) | 0 | 0 |
| Very Unwilling (Week 10) | 2.2 | 2.2 |
The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Week 5 (n=84, 82) | 2.69 ± 0.11 | 2.64 ± 0.11 |
| Week 10 (n=81, 76) | 2.31 ± 0.10 | 2.11 ± 0.11 |
The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.
| percentage of participants | Arm A | Arm B |
|---|---|---|
| Week 5 - very much improved(n=84, 82) | 11.9 | 12.2 |
| Week 5 - much worse(n=84, 82) | 44.0 | 43.9 |
| Week 5 - much improved(n=84, 82) | 31.0 | 32.9 |
| Week 5 - minimally improved(n=84, 82) | 8.3 | 9.8 |
| Week 5 - no change(n=84, 82) | 4.8 | 1.2 |
| Week 5 - minimally worse(n=84, 82) | 0.0 | 0.0 |
| Week 5 - very much worse(n=84, 82) | 0.0 | 0.0 |
| Week 5 - missing(n=84, 82) | 0.0 | 0.0 |
| Week 10 - very much improved(n=81, 76) | 25.9 | 31.6 |
| Week 10 - much improved(n=81, 76) | 46.9 | 51.3 |
| Week 10 - minimally improved(n=81, 76) | 21.0 | 15.8 |
| Week 10 - no change(n=81, 76) | 4.9 | 0.0 |
| Week 10 - minimally worse(n=81, 76) | 0.0 | 1.3 |
| Week 10 - much worse(n=81, 76) | 1.2 | 0.0 |
| Week 10 - very much worse(n=81, 76) | 0.0 | 0.0 |
| Week 10 - missing(n=81, 76) | 0.0 | 0.0 |
The Daily Sleep Interference Rating Scale (SIRS) consists of an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants described how pain had interfered with their sleep during the past 24 hours: Select the number that best describes how your pain has interfered with your sleep during the past 24 hours on a scale from 0 to 10 where 0 represents 'does not interfere with sleep' and 10 represents 'completely interferes' which means you are unable to sleep due to pain.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Week 5(n= 85, 79) | -2.46 ± 0.235 | -2.12 ± 0.236 |
| Week 10(n=81, 75) | -3.69 ± 0.265 | -3.38 ± 0.268 |
The HADS is a self-administered questionnaire measuring anxiety. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No anxiety, to 3 = Severe feelings of anxiety). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the anxiety.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Week 5 (n=84, 82) | -2.23 ± 3.78 | -1.91 ± 3.23 |
| Week 10 (n=81, 76) | -3.09 ± 4.34 | -2.68 ± 4.08 |
The HADS is a self-administered questionnaire measuring depression. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No depression, to 3 = Severe feelings of depression). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the depression.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Week 5 (n=84, 82) | -1.87 ± 4.18 | -1.35 ± 3.87 |
| Week 10 (n=81, 76) | -2.57 ± 4.62 | -2.01 ± 3.84 |
Period 1 indicates from Visit 2 (baseline) to Visit 4 (Week 5). Period 2 indicates from Visit 4 (Week 5) to Visit 6 (Week 10). A rating of 0 is considered no pain; 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.
| % of days | Arm A | Arm B |
|---|---|---|
| Period 1 (n=88, 90) (Mild) | 19.1 ± 27.88 | 15.3 ± 28.13 |
| Period 2 (n=84, 81) (Mild) | 33.5 ± 36.98 | 25.0 ± 34.50 |
| Period 1 (n=88, 90) (Moderate) | 40.2 ± 34.07 | 37.6 ± 35.23 |
| Period 2 (n=84, 81) (Moderate) | 33.2 ± 34.28 | 44.2 ± 39.41 |
| Period 1 (n=88, 90) (Severe) | 38.8 ± 40.11 | 44.8 ± 40.76 |
| Period 2 (n=84, 81) (Severe) | 26.5 ± 39.09 | 21.8 ± 34.91 |
BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the past 24 hours. The Pain severity domain: The BPI severity domain includes pain at its 'worst,' 'least,' 'average,' and 'now' (current pain) on 0-10 NRS scales and takes the mean of these 4 items. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine), therefore higher scores indicate greater pain severity.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Week 5 (n=84, 82) | -1.75 ± 2.07 | -1.68 ± 1.86 |
| Week 10 (n=81, 76) | -2.83 ± 2.26 | -2.99 ± 2.45 |
The MOS-Sleep Scale is a self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. With the exception of sleep adequacy, optimal sleep, and quantity, higher scores reflect greater impairment in the MOS-Sleep subscales. Sleep Disturbance: Range=0 to 100; higher scores indicate greater sleep disturbance. Negative changes indicate improvement.
| Units on a scale | Arm A | Arm B |
|---|---|---|
| Week 5 (n= 84, 82) | -21.3 ± 29.73 | -16.5 ± 25.92 |
| Week 10 (n= 81, 76) | -27.1 ± 25.70 | -22.8 ± 25.04 |
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| Yes (Week 5) | 51.1 | 35.6 |
| No (Week 5) | 48.9 | 64.4 |
| Yes (Week 10) | 63.6 | 58.9 |
| No (Week 10) | 31.8 | 31.1 |
The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| Yes (Week 5) | 25.0 | 20.0 |
| No (Week 5) | 75.0 | 80.0 |
| Yes (Week 10) | 42.0 | 37.8 |
| No (Week 10) | 53.4 | 52.2 |
Collected over Adverse events were reported from the signing of the informed consent throughout the study period including 28 calendar days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | — | 0/89 (0%) | 28/89 (31.5%) |
| Arm B | — | 2/91 (2.2%) | 19/91 (20.9%) |
| Event | Arm A | Arm B |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/89 | 2/91 |
| Event | Arm A | Arm B |
|---|---|---|
| DizzinessNervous system disorders | 12/89 | 12/91 |
| SomnolenceNervous system disorders | 12/89 | 7/91 |
| HeadacheNervous system disorders | 10/89 | 7/91 |
Safety population was composed of all participants who took at least one dose of study medication (either pregabalin or celecoxib).
| Age, Continuous(Years) | Arm A | Arm B | Total |
|---|---|---|---|
| Mean | 49.7 ± 11.7 | 49.2 ± 12.2 | 49.5 ± 11.9 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 65 | 63 | 128 |
| Male | 24 | 28 | 52 |
The record gives a start of Oct 2013, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →